|
Sign In to gain access to subscriptions and/or personal tools.
|
Perioperative Immunomodulation With Flt3 Kinase Ligand or a Whole Tumor Cell Vaccine Is Associated With a Reduction in Lung Metastasis Formation After Laparotomy in Mice
Joseph J. Carter, MD
Laparoscopic Physiology Laboratory, Department of Surgery, College of Physician and Surgeons, Columbia University, New York, NY; Bellevue Hospital, 27th Street and 1st Avenue, Suite 15 South-14, New York, NY 10016 cartej08{at}med.nyu.edu
Daniel L. Feingold, MD
Anthony Oh, MD
Irena Kirman, MD, PhD
Peer Wildbrett, BS
George Stapleton, BS
Zishan Asi, BA
Ryan Fowler, BS
Govind Bhagat, MD
Emina H. Huang, MD
Robert L. Fine, MD
Richard L. Whelan, MD
Laparoscopic Physiology Laboratory, Department of Surgery, College of Physician and Surgeons, Columbia University, New York, NY
Introduction:Laparotomy has been associated with temporary postoperative immunosuppression and accelerated tumor growth in experimental models. In a previous murine study, a whole cell vaccine plus the adjuvant monophosphoryl-lipid A was shown to be effective in decreasing the number of lung metastases that develop after laparotomy. This study was conducted to assess the impact of the adjuvant fetal liver tyrosine kinase 3 (Flt3) ligand on perioperative tumor growth when used alone or with a tumor cell vaccine.
Methods:An intravenous tumor cell injection lung metastases model was used. Sixty female A/J mice were divided into six equal groups designated (1) anesthesia control (AC), (2) AC with Flt3 ligand (ACFlt3), (3) sham laparotomy (OP), (4) OP with Flt3 ligand (OPFlt3), (5) OP with vaccine (OPVac), and (6) OP with Flt3 ligand and vaccine (OPFlt3Vac). Groups 2, 4, and 6 received daily intraperitoneal injections of Flt3 ligand (10µg/dose with carrier) for 5 days before and 5 days after surgery. Groups 1 and 3 received similar injections of saline on the same schedule. Groups 5 and 6 were vaccinated with irradiated whole Ta3Ha tumor cells intraperitoneally three times before and twice after surgery. Immediately after surgery, all mice were injected with 105 Ta3Ha tumor cells via a tail vein. After 14 days, the mice were sacrificed and their lungs and tracheas were excised en bloc. Specimens were stained and counterstained with India ink and Fekete solution, and surface metastases were counted by a blinded observer. Differences between study groups were determined by analysis of variance. The peritumoral inflammatory cell infiltrate of some Flt3 and control specimens was also assessed.
Results:Regarding laparotomy, Flt3 ligand (mean, 1.22 metastases), whole cell vaccine (1.12 metastases), and the combination of these two agents (0.1 metastases) were each effective in significantly decreasing the number of surface lung metastases compared with surgery alone (9.88 metastases, P < .05 for all comparisons). There were no differences between the various treatment groups in regards to number of metastases. Only the combination of Flt3 and the vaccine significantly lowered the incidence of tumors (number of mice with>1 tumors). Histologic analysis revealed that the Flt3-treated mice demonstrated increased numbers of antigen-presenting cells surrounding the tumors compared with controls.
Conclusions: Perioperative treatment with either Flt3 ligand or a whole cell tumor vaccine significantly reduced the number of lung metastases after laparotomy. The combination of the Flt3 ligand and the vaccine also decreased the incidence of metastases and was the most effective treatment. Further studies regarding perioperative immune modulation in the setting of cancer appear warranted.
Key Words: cancer metastases Flt3 ligand immunotherapy vaccine
References
- Eggermont AM, Steller EP, Marquet RL, et al. Local regional promotion of tumor growth after abdominal surgery is dominant over immuno therapy with interleukin-2 and lymphokine activated killer cells. Cancer Detect Prevent 12:421-429, 1998.
- Allendorf JD, Bessler M, Horvath KD, et al. Increased tumor establishment and growth after open versus laparoscopic bowel resection in mice. Surg Endosc 12:1035-1038, 1998.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Wildbrett P, Oh A, Carter JJ, et a. Increased rates of pulmonary metastases following sham laparotomy compared to CO2 pneumoperitoneum and the inhibition of this effect with perioperative immunomodulation. Surgical Endoscopy 16:1162-1170, 2002.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Carter J, Whelan RL. The immunologic consequences of laparoscopy in oncology. Surg Oncol Clin N Am 10:655-678, 2001.[Medline]
[Order article via Infotrieve]
- Ordemann J, Jacobi CA, Schwenk W, et al. Cellular and humoral inflammatory response after laparoscopic and conventional colorectal resections Surg Endosc 15:600-608, 2001.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Trokel MJ, Bessler M, Treat MR, et al. Preservation of immune response after laparoscopy. Surg Endosc 8:1385-1388, 1994.[Web of Science][Medline]
[Order article via Infotrieve]
- Allendorf JD, Bessler M, Whelan RL, et al. Better preservation of immune function after laparoscopic-assisted vs. open bowel resection in a murine model. Dis Colon Rectum 39(suppl):S67-S72, 1996.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Allendorf JD, Bessler M, Horvath KD, et al. Increased tumor establishment and growth after open vs laparoscopic surgery in mice may be related to differences in postoperative T-cell function. Surg Endosc 13:233-235, 1999.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Hammer JH, Nielsen HJ, Moesgaard F, et al. Duration of postoperative immunosuppression assessed by repeated delayed type hypersensitivity skin tests. Eur Surg Res 24:133-137, 1992.[Web of Science][Medline]
[Order article via Infotrieve]
- Schuurman B, Heuff G, Beelen RHJ, et al. Enhanced killing capacity of human Kupffer cells after activation with granulocyte/macrophage-colony-stimulating factor and interferon-
. Cancer 39:179-184, 1994. - Tanemura H, Sakata K, Kunieda T, et al. Influences of operative stress on cell-mediated immunity and on tumor metastasis and their prevention by nonspecific immunotherapy: experimental studies in rats. J Surg Oncol 21:189-195, 1982.[Web of Science][Medline]
[Order article via Infotrieve]
- Heys SD, Deehan DJ, Eremin O. Interleukin-2 treatment in colorectal cancer: current results and future prospects. Eur J Surg Oncol 20:622-629, 1994.[Medline]
[Order article via Infotrieve]
- Hill ADK, Redmond HP, Naama HA, et al. Granulocyte-macrophage colony-stimulating factor inhibits tumor growth during the postoperative period. Surgery 119:178-185, 1996.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Sabel M, Hill H, Jong Y, et al. Neoadjuvant therapy with interleukin-12-loaded polylactic acid microspheres reduces local recurrence and distant metastases. Surgery 130:470-478, 2001.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Braun SE. Chen K. Blazar BR, et al. Flt3 ligand antitumor activity in a murine breast cancer model: a comparison with granulocyte-macrophage colony-stimulating factor and a potential mechanism of action. Hum Gene Ther 10:2141-2151, 1999.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Small D, Levenstein M, Kim E, et al. STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. Proc Natl Acad Sci USA 91:459-464, 1994.[Abstract/Free Full Text]
- Carter JJ, Feingold DL, Wildbrett P, et al: Significant reduction of laparotomy-associated lung metastases and sub-cutaneous tumors after perioperative immunomodulation with Flt3 ligand in mice. Surg Innova 12:319-326, 2005.[CrossRef]
- Lennard TW, Shenton BK, Borzotta A, et al. The influence of surgical operations on components of the human immune system. Br J Surg 72:771-776, 1985.[Web of Science][Medline]
[Order article via Infotrieve]
- Nielsen HJ, Pedersen BK, Moesgaard F. Effect of ranitidine on postoperative suppression of natural killer cell activity and delayed hypersensitivity. Acta Chir Scand 155:377-382, 1989.[Web of Science][Medline]
[Order article via Infotrieve]
- Christou NV, Superina R, Broadhead M, et al. Postoperative depression of host resistance: determinants and effect of peripheral protein-sparing therapy. Surgery 92:786-792, 1982.[Web of Science][Medline]
[Order article via Infotrieve]
- Nielsen HJ, Moesgaard F, Kehlet H. Ranitidine for prevention of postoperative suppression of delayed hypersensitivity. Am J Surg 157:291-294, 1989.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Hjortso NC, Kehlet H. Influence of surgery, age, and serum albumin on delayed hypersensitivity. Acta Chir Scand 152:175-179, 1986.[Web of Science][Medline]
[Order article via Infotrieve]
- Mels AK, Statius Muller MG, van Leeuwen PA, et al. Immune-stimulating effects of low-dose perioperative recombinant granulocyte-macrophage colony-stimulating factor in patients operated on for primary colorectal carcinoma. Br J Surg 88:539-544, 2001.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Kirman I, Asi I, Carter J, et al. Combined whole tumor cell and monophosphoryl lipid A vaccine improved by encapsulation in murine colorectal cancer. Surg Endosc 16: 654-658, 2002.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Gray BN, Walker C, Andrewartha L, et al. Controlled clinical trial of adjuvant immunotherapy with BCG and neuraminidase-treated autologous tumour cells in large bowel cancer. J Surg Oncol 40:34-37, 1989.[Web of Science][Medline]
[Order article via Infotrieve]
- Vermorken JB, Claessen AME, van Tinteren H, et al. Active specific immunotherapy for stage II and stage III human colon cancer: a randomized trial. Lancet 353:345-350, 1999.[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Hoover HC, Hanna MG. Active immunotherapy in colorectal cancer. Semin Surg Oncol 5:436-440, 1989.[Web of Science][Medline]
[Order article via Infotrieve]
Surgical Innovation, Vol. 13, No. 1,
41-47 (2006)
DOI: 10.1177/155335060601300107

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati Twitter What's this?
|
|